| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
1 company
Donald William Nicholson is Director at GBIO. Donald William Nicholson's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $308K at current prices.
Historically, Donald William Nicholson's trades have earned a middling insider score of 52/100 across 3 rated trades. Over a 12-month horizon, 33.3% of those trades were profitable, with an average 12-month return of -11.8%.
Net of sales, the GBIO filings show accumulation of 114,500 shares.
Donald William Nicholson has 18 Form 4 filings on record from June 2020 to June 2026, across 3 companies: Director at Disc Medicine (IRON), 2022–2026; Director at Generation Bio (GBIO), 2020–2025; Director at Kymera Therapeutics (KYMR), 2020–2022.
The 19 reported transactions were 14 option or other derivative awards, 4 open-market purchases and 1 conversion.
Counted by filing, the open-market trades come to 3 purchases worth about $293K and no sales.
The largest open-market purchase was 100,000 shares of GBIO at an average $1.44 on December 1, 2023, about $144K. Twelve months later GBIO was up 9%.